Gilbert & Cook’s Vertex Pharmaceuticals VRTX Stock Holding History

Gilbert & Cook’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-784	Closed	-$276K	–	243
2023 Q2	$276K	Sell	784 -390	-33%	-$131K	0.04%	177
2023 Q1	$370K	Buy	1,174 +262	+29%	+$78.6K	0.06%	138
2022 Q4	$263K	Buy	912 +7	+0.8%	+$2.13K	0.05%	183
2022 Q3	$281K	Buy	+905	New	+$260K	0.06%	166
2020 Q4	–	Sell	-1,090	Closed	-$297K	–	193
2020 Q3	$297K	Buy	1,090 +43	+4%	+$11.9K	0.07%	111
2020 Q2	$304K	Sell	1,047 -44	-4%	-$11.9K	0.08%	94
2020 Q1	$260K	Buy	1,091 +28	+3%	+$6.42K	0.08%	91
2019 Q4	$233K	Buy	+1,063	New	+$215K	0.06%	131

Other funds holding VRTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Gilbert & Cook's VRTX Position: Q3 2023 in Review

Gilbert & Cook sold out of Vertex Pharmaceuticals (VRTX) in Q3 2023, closing a stake of 784 shares — an estimated $276K sold.

Gilbert & Cook first reported a position in VRTX in Q4 2019 and held it in 8 quarters. The position peaked at $370K in Q1 2023. 1,277 funds tracked by Wall St. Rank hold VRTX as of Q3 2023.

Gilbert & Cook reported no remaining Vertex Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Gilbert & Cook sold 784 Vertex Pharmaceuticals shares in Q3 2023, an estimated $276K.
Gilbert & Cook first reported a position in Vertex Pharmaceuticals in Q4 2019 and held it in 8 quarters.
Gilbert & Cook's Vertex Pharmaceuticals position peaked at $370K in Q1 2023.
1,277 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2023.

Based on Gilbert & Cook's 13F filing for Q3 2023, filed 2 Nov 2023.